Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "ESI Group"


3 mentions found


Outside Albany, N.Y., where hundreds of recent migrants have been bused upstate from New York City, David Buicko sees an obvious solution to the labor shortage he and other employers are experiencing. “I’d hire probably 20 people tomorrow,” said Mr. Buicko, the president of the Galesi Group, a Schenectady-based developer, who said prospective workers are still waiting for legal authorization. “It’s crazy that we can’t fill a void, we don’t have population growth, and we’ve got people that we’re just bringing in, sitting around doing nothing.”Mr. Buicko is not alone. Across the state, many large and small employers have expressed an overwhelming willingness to hire recent asylum seekers; migrants are even more eager to work. But bringing the two sides together is far harder than it might seem.
Persons: David Buicko, , , Buicko, we’ve, Mr Organizations: Galesi Locations: Albany, N.Y, New York City, Schenectady, New York, Erie
June 28 (Reuters) - Electronic equipment maker Keysight Technologies (KEYS.N) said on Wednesday it would acquire a controlling stake in French software firm ESI Group (ESIG.PA) in a 913 million euros ($995.81 million) deal. "Keysight's acquisition of ESI Group accelerates our strategy of providing software-centric solutions with virtual prototyping and advanced simulation capabilities," Keysight CEO Satish Dhanasekaran said in a statement. Once the deal is completed, Keysight will launch a mandatory tender offer for the remaining outstanding shares of ESI Group, it said. Th deal will increase Keysight's software revenue and annual recurring revenue, or ARR, Keysight said in a statement. ESI Group provides services in more than 15 countries and has about 1,000 employees.
Persons: Satish Dhanasekaran, Keysight, Th, Lavanya, Subhranshu Sahu, Rashmi Organizations: Keysight Technologies, ESI, ESI Group, Thomson Locations: California, Bengaluru
Jan 8 (Reuters) - Italy's Chiesi Farmaceutici said on Sunday it will acquire Ireland-based drugmaker Amryt Pharma Plc , which has products and drugs in development for treating rare diseases, in a deal valued at $1.48 billion. The total value of the all-cash deal represents a 107% premium over Dublin, Ireland-based Amryt's ADS closing price of $7.00 on Jan. 6, the companies said in a joint announcement. For first nine months of 2022, Amryt reported $188.8 million in revenue, and reaffirmed its full-year forecast for revenue of $260 million to $270 million. Its top-selling drug, Myalept or Myalepta, had third-quarter sales of $37.9 million. Reporting by Shivani Tanna in Bengaluru; Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.
Total: 3